Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Khon Kaen University

Abstract

Roles of recombinant human TSH (rhTSH) has been extensively studied during the past ten years in the management of patients with differentiated thyroid cancer.  Since it is convenient, safe and equally effective in the treatment with radioactive iodine and in the follow-up procedures after treatment, rhTSH has been used increasingly and is now considered a method to replace the conventional thyroid hormone withdrawal in the management of patients with differentiated thyroid cancer.  This review article aims to provide the evidence regarding the use of rhTSH in various aspects of taking care of this kind of patients, both in terms of treatment of the disease and follow-up of the disease.